Dae Duk Kim
Seoul National University · Medicine
About the Lab
Professor Dae Duk Kim's research lab specializes in pharmaceutical and translational research, focusing on the optimization of drug delivery systems for enhanced therapeutic efficacy and reduced systemic toxicity. The lab investigates novel formulations, including liposomal and nanostructured lipid carriers (NLCs), for targeted delivery of anticancer agents such as doxorubicin and photosensitizers like PPD. Key research directions include in-vitro and in-vivo evaluation of drug release profiles, pharmacokinetics, and tumor response in preclinical models, with an emphasis on interventional oncology techniques such as chemoembolization. The lab also explores the role of formulation variables—such as emulsion composition and excipients—on drug absorption and bioavailability.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Phenylboronic acid‐functionalized chondroitin sulfate A (CSA)–deoxycholic‐acid (DOCA)‐based nanoparticles (NPs) are prepared for tumor targeting and penetration. (3‐Aminomethylphenyl)boronic acid (AMPB) is conjugated to CSA–DOCA conjugate via amide bond formation, and its successful synthesis is confirmed using proton nuclear magnetic resonance spectroscopy ( 1 H‐NMR). Doxorubicin (DOX)‐loaded CSA–DOCA–AMPB NPs with a mean diameter of ≈200 nm, a narrow size distribution, negative zeta potential,
Research Areas
Dive deeper into Dae Duk Kim's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.